Pharma stocks soar 6 percent as investors respond to double dose of Good News - Business Standard
| AKUMS Stock | 455.50 17.90 3.78% |
About 62% of Akums Drugs' investor base is looking to short. The analysis of the overall prospects from investing in Akums Drugs and suggests that many traders are, at the present time, alarmed. Akums Drugs' investing sentiment overview a quick insight into current market opportunities from investing in Akums Drugs and. Many technical investors use Akums Drugs stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Akums |
Pharma stocks soar 6 percent as investors respond to double dose of Good News Business Standard
Read at news.google.com
 |
Akums Drugs Fundamental Analysis
We analyze Akums Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akums Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akums Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Akums Drugs is rated below average in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Akums Drugs Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akums Drugs stock to make a market-neutral strategy. Peer analysis of Akums Drugs could also be used in its relative valuation, which is a method of valuing Akums Drugs by comparing valuation metrics with similar companies.
Peers
Akums Drugs Related Equities
| KINGFA | Kingfa Science | 1.67 | ||||
| HEUBACHIND | Heubach Colorants | 0.54 | ||||
| DELTAMAGNT | Delta Manufacturing | 1.52 | ||||
| COSMOFIRST | COSMO FIRST | 2.96 | ||||
| GATECHDVR | GACM Technologies | 3.45 | ||||
| AKUMS | Akums Drugs | 3.78 | ||||
| TBZ | Tribhovandas Bhimji | 4.33 | ||||
| RICOAUTO | Rico Auto | 4.53 | ||||
| INNOVACAP | Innova Captab | 4.58 | ||||
| PARAGMILK | Parag Milk | 5.50 |
Other Information on Investing in Akums Stock
Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.